Business
Currency:USD
2024/Q2
Stock NameRevenueRatio
Voxzogo183.92M25.83%
Vimizim178.02M25.00%
Naglazyme132.05M18.55%
Palynziq88.29M12.40%
Brineura45.31M6.36%
ALDURAZYME38.56M5.42%
Kuvan28.55M4.01%
Royalty and other revenues9.9M1.39%
ROCTAVIAN7.43M1.04%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States771.31M31.88%
Europe669.33M27.67%
Rest of world468.21M19.35%
Latin America332.44M13.74%
Aldurazyme net product revenues marketed by Sanofi131.25M5.43%
Royalty and other revenues46.69M1.93%
View all
